Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ACELYRIN Inc | SLRN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.88 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 4.14 - 29.88 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 4.88 | USD |
ACELYRIN Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
474.04M | 97.34M | - | 0 | -381.64M | -3.92 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ACELYRIN News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SLRN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.30 | 4.95 | 4.265 | 4.59 | 970,270 | 0.58 | 13.49% |
1 Month | 5.71 | 5.74 | 4.14 | 4.67 | 1,003,831 | -0.83 | -14.54% |
3 Months | 7.49 | 8.885 | 4.14 | 6.85 | 1,281,860 | -2.61 | -34.85% |
6 Months | 8.32 | 9.25 | 4.14 | 7.04 | 1,210,638 | -3.44 | -41.35% |
1 Year | 24.69 | 29.88 | 4.14 | 11.78 | 1,114,154 | -19.81 | -80.23% |
3 Years | 23.00 | 29.88 | 4.14 | 12.07 | 1,128,580 | -18.12 | -78.78% |
5 Years | 23.00 | 29.88 | 4.14 | 12.07 | 1,128,580 | -18.12 | -78.78% |
ACELYRIN Description
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California. |